Unleashing the Power of Modular Biotherapeutics: A Look Inside Aptevo’s Innovative Technology Pipeline
Welcome to the Pep Talk 2025 Conference! Exciting News From Aptevo Therapeutics Aptevo’s Peter Pavlik, PhD, to Chair a Session on Bi and Multispecific Biologics SEATTLE, WA / ACCESSWIRE / November 26, 2024 / Aptevo Therapeutics (“Aptevo”) (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™…